*ST Ningke (600165.SH): Received a court decision to initiate the pre-restructuring of the company and appoint a temporary manager
Gelonghui, May 31,*ST Ningke (600165.SH) announced that the company received the (2024) Ning 02 Bashen 1 “Decision” and (2024) Ning 02 Bashen 2 “Decision” issued by the court. After the review, it was decided to start a pre-restructuring procedure for Ningxia Zhongke Biotechnology New Materials Co., Ltd. The pre-restructuring period is no more than six months. The court appointed the liquidation team set up by the Huinong District People's Government as the temporary manager of Ningxia Zhongke Biotechnology New Materials Co., Ltd.
*ST Ningke (600165.SH): There is significant uncertainty about the restructuring, and there is a risk of bankruptcy due to failure of the restructuring
*ST Ningke (600165.SH) issued an announcement. The company's stock fell to a halt on May 10, 2024, at 2...
*ST Ningke (600165.SH) was sued by the Huinong District Branch of the Bank of China due to a loan contract dispute involving 187 million yuan
Zhitong Finance App News, *ST Ningke (600165.SH) issued an announcement. Due to a financial loan contract dispute, the Huinong District Branch of the Bank of China filed a “Civil Complaint” with the Shizuishan Intermediate People's Court as a plaintiff to file lawsuits against the defendants Shanghai Zhongneng Enterprise Development (Group) Co., Ltd. (Shanghai Zhongneng), Yu Jianming, the company, Zhongke New Materials, and Huahui Environmental Protection. The amount involved was RMB 187 million. According to reports, under its name, Zhongke New Materials (Ning (2020)) Shizuishan Real Estate Rights No. H0001453, H0001420, H0001447, and H0001
Debt risk intensified*ST Ningke (600165.SH) subsidiary Zhongke New Materials was required to repay a total of 195 million yuan in loan principal and interest in advance
*ST Ningke (600165.SH) issued an announcement. The company and its holding subsidiary Ningxia Zhongke Biotechnology New Materials Co., Ltd...
*ST Ningke (600165.SH) intends to apply to the court for reorganization and pre-restructuring
*ST Ningke (600165.SH) issued an announcement. There is uncertainty about whether the company can completely resume work and resume production, and maintain...
With A 57% Price Drop For Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165) You'll Still Get What You Pay For
Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165) shares have had a horrible month, losing 57% after a relatively good period beforehand. For any long-term shareholders, the last month ends a ye
ST Ningke (600165.SH) announced first-quarter results with a net loss of 51.4546 million yuan
ST Ningke (600165.SH) released its report for the first quarter of 2024, with revenue of 53.8967 million...
ST Ningke (600165.SH), which fell to a halt for 14 consecutive years, and its subsidiary Zhongke New Materials were applied for pre-restructuring by creditors
ST Ningke (600165.SH) issued an announcement. On April 22, 2024, the company and its subsidiary Ningxia Zhongke...
Chinese Securities Regulator Warns Zhongke Biotechnology Over Late Disclosure of Unit's Suspension
Ningxia Zhongke Biotechnology (SHA:600165) received a warning from the China Securities Regulatory Commission for not disclosing the suspension of its unit, Ningxia Zhongke Bio-New Materials, in a tim
7 Lianbanningke Biotech (600165.SH): There may be a risk of a decline after a large short-term increase
Ningke Biotech (600165.SH) issued an announcement. The daily closing price increase of the company's stock was off for 10 consecutive trading days...
5 Lianban Ningke Biotech (600165.SH): The subsidiary Zhongke New Materials has been temporarily discontinued until now
Zhitong Finance App News, Ningke Biotech (600165.SH) issued an announcement. The company's holding subsidiary Zhongke New Materials entered a state of discontinuation of production after completing the packaging and storage of the current batch of products on February 7, 2024. Up to now, production has been temporarily discontinued. On February 26, 2024, the core management personnel and technicians of Zhongke New Materials arrived to carry out production equipment inspection work as needed. The main production personnel have not yet arrived. On March 9, 2024, front-end production preparations such as strain activation and expansion began. Up to now, the strain activation and expansion work has been completed, and students will need to be initiated in the future according to the investment of relief funds
Ningxia Zhongke Biotechnology Co., Ltd's (SHSE:600165) P/S Is Still On The Mark Following 30% Share Price Bounce
Those holding Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165) shares would be relieved that the share price has rebounded 30% in the last thirty days, but it needs to keep going to repair the rec
Court Orders Freezing of Zhongke Biotechnology's Bank Accounts Worth 2.6 Million Yuan
A court ordered freezing Ningxia Zhongke Biotechnology's (SHA:600165) bank accounts with up to 2.6 million yuan in funds in relation to a loan dispute lodged by Ningxia Huanghe Rural Commercial Bank,
Zhongke Biotechnology's Chairman Resigns
Wu Jiangming resigned as chairman of Ningxia Zhongke Biotechnology (SHA:600165) due to personal reasons. The board Chinese biotechnology company plans to hold an election to name Wu's successor. Pric
Ningke Biotech (600165.SH): Chairman Wu Jiangming resigns
Gelonghui, Feb. 19: Ningke Biotech (600165.SH) announced that it received the resignation report from Mr. Wu Jiangming, the chairman of the company. Mr. Wu Jiangming submitted a resignation report to the company's board of directors due to personal reasons and resigned as chairman, member of the nomination committee, and member of the remuneration and assessment committee. After resigning from these positions, Mr. Wu Jiangming continued to serve as a director of the company and a member of the Strategy Committee. Mr. Hu Chunhai was elected as the chairman of the 9th board of directors of the company. The term of office is the same as the term of the 9th board of directors.
Ningxia Zhongke Biotechnology Co., Ltd's (SHSE:600165) 27% Cheaper Price Remains In Tune With Revenues
Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165) shareholders that were waiting for something to happen have been dealt a blow with a 27% share price drop in the last month. For any long-term s
Ningke Biotech (600165.SH): Pre-loss of 350 million yuan to 500 million yuan in 2023
Gelonghui, January 30丨Ningke Biotech (600165.SH) announced the 2023 annual results pre-loss announcement. According to preliminary estimates by the financial department, it is estimated that net profit attributable to shareholders of listed companies will be about -50 million yuan to -350 million yuan in 2023. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss is about -50 million yuan to -350 million yuan.
Ningke Biotech (600165.SH) terminates debt settlement agreement with Shizuishan Zhengxingcheng New Materials Technology Partnership
Ningke Biotech (600165.SH) announced that the company will hold the 9th board meeting on November 23, 2023...
[BT Financial Report Instantaneous Analysis] Ningke Biotech's 2023 Quarterly Report: Facing challenges, declining performance, what about the future?
This financial report was announced at 17:39:57 2023-10-27, 17:39:57 Ningke Biotech (stock code: 600165) is an enterprise focusing on the manufacture of bio-based and starch-based new materials. Its holding subsidiary Zhongke New Materials is mainly engaged in the production and sale of long-chain binary acids. Long-chain binary acid is a new bio-based material with a wide range of applications. It is widely used in high-end energy, new energy vehicles, chemicals, light industry, agriculture, medicine, LCD materials, military industry, aerospace and other high-tech material industries. The company uses biotechnology to produce long-chain binary acids on a large scale, and has mild production conditions
Ningke Biotech (600165.SH): Net loss of 137 million yuan in the first half of the year
On August 14, GLONGHUI | Ningke Biotech (600165.SH) released its 2023 semi-annual report. The reporting period achieved operating income of 102 million yuan, a year-on-year decrease of 78.54%; net profit attributable to shareholders of listed companies - 137 million yuan, turning losses year on year; net profit attributable to shareholders of listed companies - 132 million yuan after deducting non-recurring profit and loss; basic earnings per share - 0.200 yuan.
No Data